Market Overview

Bonti Announces Hot Topics Presentation Featuring EB-001 at Plastic Surgery The Meeting

Share:

Positive Phase 2 Proof of Concept Clinical Data Paves the Way for
Therapeutic Musculoskeletal Pain Management and for Further Facial
Aesthetic Studies

Bonti, a privately-held, clinical-stage biotechnology company, today
announced a Hot Topics presentation featuring proof of concept clinical
results for its lead product EB-001 at Plastic Surgery The Meeting on
October 6th in Orlando, FL. Dr. Brian Kinney presented EB-001
study findings and their clinical and commercial significance at this
premier educational and networking event which was organized by the
American Society of Plastic Surgeons (ASPS), The Plastic Surgery
Foundation (The PFS) and The American Society of Maxillofacial Surgeons
(ASMS). EB-001 is a novel serotype E botulinum neurotoxin
(BoNT/E) with a unique product profile, characterized by fast onset of
action (within 24 hours) and short duration of effect (about 4 weeks).
With the benefits of this profile in mind, EB-001 is being developed for
therapeutic and aesthetic indications with significant addressable
market opportunities.

Dr. Kinney, a board-certified plastic surgeon, whose practice is in
Beverly Hills, CA, and a Clinical Associate Professor of Plastic Surgery
at the University of Southern California (USC), spotlighted Phase 2
proof of concept clinical data illustrating that, as previously
announced, the first in human EB-001 study achieved its objectives and
confirmed both the favorable safety and the expected clinical efficacy
profile. He addressed how EB-001 is being developed to establish it for
exclusive and complementary facial aesthetic uses with unmet needs. Dr.
Kinney also outlined how the dosing data from the proof of concept study
confirmed dose selection so Bonti could start the therapeutic LANTERN-1
Phase 2 clinical study evaluating EB-001 in reducing musculoskeletal
pain.

"We're grateful to the ASPS for selecting EB-001 for the Hot Topics
track and we were privileged to have Dr. Kinney share EB-001's potential
prospects for both therapeutic and aesthetic applications with his peers
in the plastic surgery community attending this prestigious conference,"
commented Fauad Hasan, CEO at Bonti. "We believe EB-001 will help expand
the aesthetic market by serving as an additional tool for plastic
surgeons looking for innovative ways to address their patients' facial
aesthetic needs not tackled by current marketed products. Furthermore,
EB-001 also has the potential to be a long-acting, non-opioid solution
for treating focal musculoskeletal pain resulting after various plastic
and reconstructive surgeries, which account for about 15% of our
approximately 12 million target surgical procedures each year in the
U.S."

"My excitement surrounding EB-001 is based on the strong clinical proof
of concept data which may conceivably lead to new treatment paradigms,"
said Dr. Kinney, a world renowned, board-certified plastic surgeon, past
member of the Board of Directors of the American Society of Plastic
Surgeons and a Past President of the Plastic Surgery Educational
Foundation of the United States. "Both the pain relief and the aesthetic
applications for EB-001 may be game changing because of the potential
benefits delivered by the drug's unique fast onset and short duration
target clinical profile. EB-001 may be a significant addition to our
post-surgical multi-modal pain management options to treat pain
effectively while helping to address the opioid epidemic. And from a
cosmetic perspective, the prospect for EB-001 to solve current problems
so patients look their best and have the highest satisfaction possible
is promising."

About EB-001

Bonti's lead product candidate, EB-001, is an investigational botulinum
neurotoxin serotype E (BoNT/E). EB-001 has a mechanism of action similar
to the marketed botulinum neurotoxin serotype A (BoNT/A) products
though it has a differentiated clinical profile. EB-001 has a fast onset
of action (within 24 hours) and short duration of effect (about 4
weeks). Currently marketed BoNT/A products have an onset of action
around 3-7 days and a duration of effect around 3-4 months. The unique
target clinical profile of EB-001 may be well suited for a vast range of
aesthetic and therapeutic uses, including for the treatment of
post-surgical and non-surgical musculoskeletal pain, with currently
unmet needs.

About Bonti

Bonti, based in Newport Beach, California, is a rapidly emerging
biotechnology company founded by world class neurotoxin experts with
proven success at Allergan, one of the Fortune 500 fastest growing
pharma companies. This team, with unsurpassed neurotoxin, aesthetic and
pain expertise, is uniquely qualified to develop unprecedented treatment
paradigms driven by a novel neurotoxin platform to become an innovative
leader in both aesthetic and therapeutic markets. By turning the science
of neurotoxins into beneficial patient and healthcare provider
solutions, Bonti will improve lives by successfully addressing key unmet
needs in markets with significant addressable opportunities.

For more information, please visit http://bonti.com.

View Comments and Join the Discussion!
 

Partner Center

Loading...